English
Regional settings| Spread | 0.05 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 1.74 |
| Open | 1.75 |
| 1-Year Change | -21.52% |
| Day's Range | 1.72 - 1.82 |
Tilray Inc. (TLRY) is a pharmaceutical company that is engaged in the research, cultivation, production and distribution of medical and recreational cannabis and cannabinoids. The firm operates through two key divisions – Cannabis and Hemp – and runs a diversified portfolio of brands, including Canaca, Dubon, Yukon Rove and Manitoba Harvest. Its products are available to hospitals, pharmacies, physicians and patients, as well as researchers.
Incorporated in the US and headquartered in Canada, Tilray has presence in a number of countries, including Argentina, Chile, Australia, New Zealand, Germany, Cyprus, Switzerland, UK, Ireland, Portugal and South Africa.
Tilray stock is listed on the Nasdaq Stock Market under the ticker symbol TLRY.
Watch the TLRY share price in real-time at Capital.com.
The company was founded in 2013 as a subsidiary of US-based Privateer Holdings, a private equity firm that invests exclusively in the cannabis industry.
In 2018, Tilray partnered with Sandoz, a subsidiary of Novartis (NOVN), to co-brand and distribute Tilray's non-smokable medical cannabis products in legal markets globally. It also announced a $100m joint venture with AB InBev, the world's largest brewer.
In 2019, it signed a $250m revenue-sharing deal with New York City-based Authentic Brands Group (ABG) to leverage its brand names to develop, market and distribute cannabis products. Also in 2019, Tilray acquired Smith & Sinclair, FOUR20, Natura Naturals Holdings and Manitoba Harvest.
In December 2020, the company announced its plans to merge with Aphria to create the world’s largest cannabis company by revenue that would continue operating under Tilray's name and trade as TLRY.
With Capital.com’s Tilray stock chart you can not only quickly view the current TLRY share price, but also trace the company’s share value in historic terms.
In July 2018, Tilray became the first pure-play cannabis company to go public on a major US stock exchange, floating its shares on the Nasdaq exchange at a price of $17 per share. In its first day of trading, the company's stock gained more than 30 per cent, closing at $22.39. But after experiencing a stellar rise to $300 per share by September 19, 2018, it entered a downtrend. With the exception of occasional upside fluctuations, the Tilray stock price was falling steadily, bottoming out at $2.43 in March 2020 in the market’s initial reaction to the Covid-19 pandemic.
Throughout 2020, TLRY stock had mainly traded below the $10 per share level, closing the year at $9 per share. In January 2021, the share price doubled from $9 to $18, soaring to close at $63.91 per share on February 10. The rally was driven by the warming political landscape for cannabis producers, as well as Reddit-backed retail investors who, at that time, short-squeezed a number of stocks, including GameStop (GME) and AMC Entertainment (AMC). The momentum was short-lived and by February 12, 2021, TRLY shares closed the trading session at $29.
You can go long or short on the company’s shares using Capital.com’s proprietary trading platform.
